These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29302264)

  • 1. The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty.
    Yoon JW; Park HA; Lee J; Kim JH
    Korean J Pediatr; 2017 Dec; 60(12):395-402. PubMed ID: 29302264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty.
    Kim HR; Nam HK; Rhie YJ; Lee KH
    Ann Pediatr Endocrinol Metab; 2017 Dec; 22(4):259-265. PubMed ID: 29301187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal assessment of auxological parameters, adult height outcome and its determinants in leuprolide-treated Indian girls with idiopathic central precocious puberty.
    Mondkar S; Khadilkar V; Yewale S; Dange N; More C; Khadilkar A
    J Pediatr Endocrinol Metab; 2024 Jan; 37(1):62-68. PubMed ID: 38008794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.
    Lerman L; Yackobovitch-Gavan M; Phillip M; Shalitin S
    Pediatr Res; 2024 Mar; 95(4):1051-1059. PubMed ID: 37935883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty.
    Yang WJ; Ko KH; Lee KH; Hwang IT; Oh YJ
    Ann Pediatr Endocrinol Metab; 2017 Mar; 22(1):49-54. PubMed ID: 28443259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of GnRH agonist treatment on body mass index in girls with idiopathic central precocious puberty.
    Vuralli D; Ozon ZA; Gonc EN; Alikasifoglu A; Kandemir N
    J Pediatr Endocrinol Metab; 2020 Jan; 33(1):99-105. PubMed ID: 31804960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near final adult height, and body mass index in overweight/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs.
    Sinthuprasith P; Dejkhamron P; Wejaphikul K; Unachak K
    J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1369-1375. PubMed ID: 31605579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty.
    Park J; Kim JH
    Ann Pediatr Endocrinol Metab; 2017 Mar; 22(1):27-35. PubMed ID: 28443256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty.
    Jeon MJ; Choe JW; Chung HR; Kim JH
    Ann Pediatr Endocrinol Metab; 2021 Sep; 26(3):171-177. PubMed ID: 34015908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index evolution and ovarian function in adolescent girls who received GnRH agonist treatment for central precocious puberty or early and fast puberty.
    Buyukyilmaz G; Koca SB; Adiguzel KT; Gurbuz F; Boyraz M
    J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1044-1051. PubMed ID: 37735929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level.
    Park J; Hwang TH; Kim YD; Han HS
    Ann Pediatr Endocrinol Metab; 2018 Mar; 23(1):14-20. PubMed ID: 29609441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty.
    Kim SW; Kim YB; Lee JE; Kim NR; Lee WK; Ku JK; Kim EJ; Jung SH; Chung WY
    Ann Pediatr Endocrinol Metab; 2017 Jun; 22(2):95-101. PubMed ID: 28690987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone.
    Jung MK; Song KC; Kwon AR; Chae HW; Kim DH; Kim HS
    Ann Pediatr Endocrinol Metab; 2014 Dec; 19(4):214-9. PubMed ID: 25654068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls.
    Shiasi Arani K; Heidari F
    Int J Endocrinol Metab; 2015 Jul; 13(3):e23085. PubMed ID: 26401141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty.
    Kim EY
    Korean J Pediatr; 2015 Jan; 58(1):1-7. PubMed ID: 25729392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy.
    Lim KI; Lee HS; Hwang JS
    Ann Pediatr Endocrinol Metab; 2020 Sep; 25(3):169-173. PubMed ID: 33017886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the resilience of the girls with central precocious puberty treated with gonadotropin-releasing hormone analog.
    Odabasi Gunes S; Akin O; Eray S
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1379-1384. PubMed ID: 34313086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.